Revolutionize cancer screening

Screening for a signal shared by 50+ cancers is now possible with the Galleri test - all with a single blood draw.1

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative signal results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Female physician in a white lab coat with gray hair sitting at a table in front of a tablet smiling at a person who is off camera

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative signal results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancer screening today: Too little, too late

~70%

of cancer deaths are caused by cancers without recommended screening.2*


1 in 5

people will die from cancer, one of the leading causes of death in the U.S.3,4


*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cases

close-up image of two people holding hands

Why is early detection important?

purple text indicating 92%

Patient experience

Give patients more control of their health. 92% of people want to know if they have cancer as early as possible.5

purple text indicating 4x

Health outcomes

When diagnosed early, the 5-year cancer-related survival rate is 4x higher than when diagnosed in later stages.6

purple text indicating 3 in 4

Provider & staff satisfaction

3 in 4 employees agreed they would be more satisfied with their employer with a multi-cancer early detection test as a benefit.7†

purple text indicating 3x

Costs of care

Early-stage cancer is an average of 3x less expensive to treat vs late-stage in the first year after diagnosis.8

Market research included 1,000 respondents, age 40+, employed full-time at organizations with 3k+ employees.

Patients deserve more

See the unseen with Galleri

The first of its kind, the Galleri test gives you the power to screen early for a signal shared by 50+ types of cancer - all with a single blood draw.1

If a cancer signal is detected, the Galleri test predicts its origin with high accuracy to help guide the next steps to diagnosis.9

Join thousands of patients and providers using Galleri

  • 100,000+ tests10
  • 7,100+ ordering providers10

In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with "Cancer Signal Detected" test result

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative signal results do occur.

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Get started with Galleri

Leading organizations are using the Galleri test to screen for cancer early, including: 

Increase the chances of successful treatment with early cancer screening

blue circle graphic with a icon of person next to a small heart with a plus sign inside of it

The Galleri test could result in a 26% reduction in 5-year cancer-related mortality when added to usual care (based on modeled data)11

blue circle graphic with a five pointed star icon inside of it

97% patient satisfaction with Galleri12‡

“I feel like this test was made for me and I appreciate it so much. I’m going to be able to live my life because we found it so soon.”

Valerie

B roll still image of Galleri patient Valerie outside wearing a scarf and knit hat

The PATHFINDER study was conducted with an earlier version of Galleri. Participants responding satisfied, very satisfied, or extremely satisfied to the following question: “Taking all things into account, how satisfied or dissatisfied are you with the multi-cancer early detection test?”

Support your workforce

illustrated graphic of the Galleri test box sitting on a table in front of a window

9 in 10 providers are satisfied with the Galleri test.13§

illustrated graphic of a white, gray haired female patient having her blood drawn

Employees rank the Galleri test as the #1 most important benefit (in market research).7

illustrated graphic of a Black male doctor in a white lab coat reading a chart

GRAIL supports your providers with robust education and assistance with positive test results

Illustrated graphic of a tan female doctor with brown hair and blue glasses reviewing the results of a Galleri test

Galleri embeds into provider workflows with EHR integration for ordering and return of results

§Healthcare Provider Customer Satisfaction Report, fielded May 23 through June 12, 2022. n=171 Healthcare Providers completed the survey; N=4726 Galleri-onboarded healthcare providers were invited to complete the satisfaction survey. Includes providers who answered 'somewhat satisfied' and 'extremely satisfied' to the question "How satisfied are you with your overall experience with the Galleri test?"
Market research included 1,000 respondents, age 40+, employed full-time at organizations with 3k+ employees.

"I strongly believe that because of the Galleri test, the lesion was detected early and was successfully treated. Without that, we would have probably faced much more complicated therapy."

Martin Poliak, MD, Internal Medicine

Video still of Galleri Case Series with Dr. Poliak indicating a cancer signal detected with a cancer signal origin of liver, bile duct

Drive success across your system

blue circle graphic around a love heart icon with an EKG heartbeat line through the center

Through stage-shifting with Galleri,11 two stage II patients may be treated with the same resources as one stage IV patient. This can help reduce treatment costs.8

blue circle graphic with hospital icon in the center

3 in 4 patients say access to innovative screenings is important for choosing a new PCP.14 Galleri can help attract and retain patients to your organization.**

blue circle graphic surrounding a hexagon icon with a plus sign in the center

GRAIL helps raise awareness of the Galleri test in your market. Continuous support and analytics from GRAIL help drive success.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Based on modeled data. Data on stage-specific incidence and 5-year survival of all invasive cancers in people aged 50–79 years diagnosed between 2006–2015. Performance of MCED test in a state-transition model (interception model) when added to usual care.
**Study demographics included 1,001 respondents, age 50+, including high-risk individuals age 35-49 (n=150). Respondents had private or commercial health insurance, Medicare, or government insurance coverage and had visited a PCP in the past two years. Data shown reflects MaxDiff relative utility values (n=1,001).

“I tell them this is a unique opportunity. We’re the only health system in this city that has availability of this blood test that can detect a shared cancer signal across 50-plus different types of cancer. It’s no cost because of a grant from our foundation. Then I ask, ‘Is this something that you’re interested in doing?’ And they always say yes.”

Patrick McGill, MD, Executive Vice President & Chief Transformation Officer at Community Health Network

Headshot of Patrick McGill, MD, Executive Vice President & Chief Transformation Officer at Community Health Network

Learn more

To connect with GRAIL, please fill out this form.

If you are a concierge, private, or group practice provider, complete this form instead.

  1. What describes you best?

  2. What are you looking for?

  3. Fill in the form

    If you are a concierge, private, or group practice provider, complete this form instead.

    We care about your privacy. Our Privacy Policy

    We care about your privacy. Our Privacy Policy

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.

  2. Estimated deaths per year in 2021 from American Cancer Society Cancer Facts and Figures 2021. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html.

  3. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html.

  4. Leading Causes of Death https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.

  5. Market research GRAIL, LLC data on file GA-2022-0089.

  6. Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. ​“Early/​Localized” includes invasive localized tumors that have not spread beyond organ of origin. ​“Late/​Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body. Data on file GA-2021-004.

  7. GRAIL, LLC Data on File GA-2022-0089.

  8. Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. DOI: doi.org/10.1080/03007995.2022.2047536.

  9. Schrag D, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.

  10. GRAIL, LLC Data on File GA-2022-0078.

  11. Hubbell E, Clarke C, Aravanis A, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30:460-8. DOI: doi.org/10.1158/1055-9965.EPI-20-1134.

  12. Schrag D, et al. Evaluation of Anxiety, Distress and Satisfaction Using a Multi-Cancer Early Detection (MCED) Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.

  13. GRAIL, LLC Data on File GA-2023-0109.

  14. GRAIL, LLC Data on File GA-2021-0072-MR.